Allianz Asset Management GmbH - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2022$711,000
-6.7%
12,4500.0%0.00%0.0%
Q1 2022$762,000
+16.9%
12,4500.0%0.00%
Q4 2021$652,000
+40.5%
12,4500.0%0.00%
Q3 2021$464,000
-37.7%
12,450
-31.8%
0.00%
-100.0%
Q2 2021$745,000
-28.9%
18,250
-40.9%
0.00%0.0%
Q1 2021$1,048,000
+6.7%
30,8850.0%0.00%0.0%
Q4 2020$982,000
+23.8%
30,8850.0%0.00%0.0%
Q3 2020$793,000
+74.7%
30,885
+74.9%
0.00%0.0%
Q2 2020$454,000
-17.6%
17,659
-50.7%
0.00%0.0%
Q1 2020$551,000
-43.7%
35,831
+25.6%
0.00%0.0%
Q4 2019$979,000
+248.4%
28,522
-24.1%
0.00%
Q3 2019$281,000
+8.1%
37,564
+87.6%
0.00%
Q2 2019$260,000
-76.3%
20,020
-49.3%
0.00%
-100.0%
Q1 2016$1,097,000
-87.5%
39,452
-75.8%
0.00%
-90.0%
Q4 2015$8,786,000
+14.1%
163,336
-15.0%
0.01%
+11.1%
Q3 2015$7,697,000192,2380.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders